Efficacy and Safety of Intravenous Emphasis Type=

Authors: F Catalino S Scarponi F Cesa G Loiacono M Bortolini

Publish Date: 2012/10/26

Volume: 4, Issue: 4, Pages: 78-82

PDF Link

Abstract

Intrahepatic cholestasis of pregnancy ICP requires the earliest possible treatment as it increases the risk of premature delivery and fetal distress Furthermore the severity of pruritus in ICP may interfere with the mother’s wellbeing We present results of a trial involving an additional 55 cases of ICP mean age 29 years who received SAMe 800 mg/day intravenously at the onset of ICP for 10 to 30 days Clinical assessment of pruritus and measurements of serum total bile salts STBS serum total and conjugated bilirubin STB SCB serum alkaline phosphatase SAP and aspartate and alanine aminotransferases AST ALT were performed before and after therapy SAMe treatment significantly p 001 decreased STBS 183 ± 34 vs 231 ± 34 μmol/L SCB 78 ± 08 vs 107 ± 12 μmol/L SAP 47 ± 02 vs 61 ± 03 μkat/L AST 09 ± 01 vs 20 ± 02 μkat/L and ALT 16 ± 01 vs 29 ± 02 μkat/L levels compared with basal values At baseline most patients exhibited normal STB and therefore no significant change in this parameter was recorded after therapy Pruritus was significantly improved after SAMe treatment and was reduced in 15 patients and had disappeared in 40 patients No adverse reactions were observed There were no cases of premature labour and all newborns had normal Apgar scores mean 82 and were of normal weight for gestational age These results further support the use of SAMe therapy in ICP

Keywords: